Leukemia and Lymphoma

Patients with acute myeloid leukemia (AML) who have undergone intensive chemotherapy are at a very high risk for invasive fungal disease, and a changing treatment landscape warrants further research on drug-drug interactions and outcomes.

Among a cohort of 88 patients with acute myeloid leukemia who received hypomethylating agents with venetoclax prior to allogeneic hematopoietic cell transplant, 85% had achieved morphologic complete response at 100 days.

Bernice Kwong, MD, clinical professor of dermatology, Stanford University, explains what dermatological considerations should be made for patients with leukemia and lymphoma.

Acute myeloid leukemia is a complicated heterogenous hematological cancer with a poor prognosis, but novel targets may lead to improved treatment and outcomes going forward.

Aldo-keto reductase 1C3 (AKR1C3) has been identified as a potential biomarker and target in several cancers, and a recent study found it to be a potential biomarker in T acute lymphoblastic leukemia/lymphoma (T-ALL).

With an increasing number of longer-term survivors treated with chimeric antigen receptor (CAR) T-cell therapy for non-Hodgkin lymphoma (NHL), more research is needed to confirm its effects on neurocognitive performance.

Joseph Alvarnas, MD, vice president of government affairs at City of Hope and chief clinical adviser of AccessHope in Duarte, California, spoke March 4 at the closing session of the Association for Community Cancer Centers (ACCC) Annual Meeting & Cancer Business Summit in Washington, DC.

Results of the phase 3 ALPINE trial provided found zanubrutinib was superior to ibrutinib in overall response rate.

The researchers found that the prognostic values for both overall and progression-free survival remained even after adjusting for the International Prognostic Index, a widely used prognostic model of outcomes for the disease.

With further research, allogeneic CAR T-cell therapy may help overcome the cost and production time barriers currently associated with autologous CAR T-cell therapy.

Across all measures, researchers found that body mass index in young adults had the strongest association with the risk of non-Hodgkin lymphoma (NHL), estimating that 23.3% of diffuse large B-cell lymphoma (DLBCL) cases and 11% of NHLs overall can be attributed to obesity.

Investigators say it may soon be possible to design therapies better at staving off resistance among patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (LPL/WM), which is an incurable disease.

Retrospective study findings show that CD47 expression on Hodgkin and Reed–Sternberg (HRS) cells varied between patients who had classical Hodgkin lymphoma (HL) and was associated with poor outcomes.

The authors of a new study say patients with certain mutations appear to respond to zanubrutinib, which had a favorable safety profile.

A recent review examined currently approved treatments and those under investigation for mantle cell lymphoma.

Approaches such as new types of monoclonal antibodies and chimeric antigen receptor natural killer cells could change how chronic lymphocytic leukemia is treated, according to a recent review article.

About 15% of cases of large granular lymphocytic leukemia involve natural killer cells.

Low-burden mutations, or minor clones, of TP53 abnormalities were once thought to be of little significance but that is no longer the case, according to a recent report.

Not all Guillain-Barré cases are associated with infection, and studies have suggested a link between the rare disorder and certain cancers, including lymphomas.

The supplemental new drug application (sNDA) filing includes data from 2 pivotal randomized phase 3 global studies, ALPINE and SEQUOIA, of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). The target action date is October 22, 2022.

The mutation is more common than expected and associated with poor outcomes, according to researchers from St. Jude Children’s Research Hospital.

Primary central nervous system non-Hodgkin lymphomas are rare extranodal B-cell lymphomas with a poor prognosis and no standard treatment plan.

The new protocol for monitoring acute lymphoblastic leukemia (ALL) is simpler than current techniques and is at least as good as the current gold standard.

Health state utilities can be used to examine and compare the cost-effectiveness of the chimeric antigen receptor (CAR) T-cell therapies for large B-cell lymphoma (LBCL) as more become available.

Researchers, as well as a patient who had chronic lymphocytic leukemia (CLL), hailed the findings as a cure, although more work needs to be done to see if the results persist in a larger group of patients.

Incyte has become the latest company to pull an FDA filing following Gilead and Secura Bio, which both voluntarily withdrew therapies that had been granted accelerated approval but hadn’t completed confirmatory studies for full approval.

A presentation at the 63rd American Society of Hematology (ASH) annual meeting explored the collection of real-world data.

Zanubrutinib is a second-generation Bruton tyrosine kinase (BTK) inhibitor that has fewer off-target effects and less cardiotoxicity than ibrutinib, a first-generation BTK inhibitor.

The data published in Scientific Reports are the first to implicate a role for RASGRP4 mutations in B-cell malignancies.